Logo image of IRIX

IRIDEX CORP (IRIX) Stock Fundamental Analysis

NASDAQ:IRIX - Nasdaq - US4626841013 - Common Stock - Currency: USD

1.03  +0.01 (+0.98%)

Fundamental Rating

1

Overall IRIX gets a fundamental rating of 1 out of 10. We evaluated IRIX against 191 industry peers in the Health Care Equipment & Supplies industry. IRIX may be in some trouble as it scores bad on both profitability and health. IRIX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IRIX has reported negative net income.
IRIX had a negative operating cash flow in the past year.
In the past 5 years IRIX always reported negative net income.
In the past 5 years IRIX reported 4 times negative operating cash flow.
IRIX Yearly Net Income VS EBIT VS OCF VS FCFIRIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

1.2 Ratios

IRIX has a Return On Assets of -30.58%. This is comparable to the rest of the industry: IRIX outperforms 43.98% of its industry peers.
With a Return On Equity value of -424.89%, IRIX is not doing good in the industry: 83.77% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -30.58%
ROE -424.89%
ROIC N/A
ROA(3y)-25.41%
ROA(5y)-21.92%
ROE(3y)-189.74%
ROE(5y)-125.62%
ROIC(3y)N/A
ROIC(5y)N/A
IRIX Yearly ROA, ROE, ROICIRIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

The Gross Margin of IRIX (40.07%) is worse than 69.11% of its industry peers.
In the last couple of years the Gross Margin of IRIX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for IRIX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 40.07%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.83%
GM growth 5Y-0.6%
IRIX Yearly Profit, Operating, Gross MarginsIRIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

1

2. Health

2.1 Basic Checks

IRIX does not have a ROIC to compare to the WACC, probably because it is not profitable.
IRIX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IRIX has been increased compared to 5 years ago.
The debt/assets ratio for IRIX is higher compared to a year ago.
IRIX Yearly Shares OutstandingIRIX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
IRIX Yearly Total Debt VS Total AssetsIRIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -2.83, we must say that IRIX is in the distress zone and has some risk of bankruptcy.
IRIX has a Altman-Z score of -2.83. This is in the lower half of the industry: IRIX underperforms 62.30% of its industry peers.
A Debt/Equity ratio of 0.48 indicates that IRIX is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.48, IRIX perfoms like the industry average, outperforming 41.88% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Altman-Z -2.83
ROIC/WACCN/A
WACC8.98%
IRIX Yearly LT Debt VS Equity VS FCFIRIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 1.42 indicates that IRIX should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.42, IRIX is doing worse than 74.87% of the companies in the same industry.
IRIX has a Quick Ratio of 1.42. This is a bad value and indicates that IRIX is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.77, IRIX is not doing good in the industry: 84.29% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.42
Quick Ratio 0.77
IRIX Yearly Current Assets VS Current LiabilitesIRIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

IRIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.47%, which is quite good.
The Revenue has decreased by -6.19% in the past year.
Measured over the past years, IRIX shows a small growth in Revenue. The Revenue has been growing by 2.29% on average per year.
EPS 1Y (TTM)8.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.22%
Revenue 1Y (TTM)-6.19%
Revenue growth 3Y-3.35%
Revenue growth 5Y2.29%
Sales Q2Q%1.94%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y49%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year5.44%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IRIX Yearly Revenue VS EstimatesIRIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
IRIX Yearly EPS VS EstimatesIRIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IRIX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IRIX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IRIX Price Earnings VS Forward Price EarningsIRIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IRIX Per share dataIRIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IRIX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IRIDEX CORP

NASDAQ:IRIX (4/21/2025, 8:23:00 PM)

1.03

+0.01 (+0.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)05-08 2025-05-08/amc
Inst Owners19.45%
Inst Owner Change0%
Ins Owners3.68%
Ins Owner Change2.13%
Market Cap17.29M
Analysts43.33
Price Target2.04 (98.06%)
Short Float %2.02%
Short Ratio5.64
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.21%
Min EPS beat(2)-30.72%
Max EPS beat(2)18.3%
EPS beat(4)1
Avg EPS beat(4)-28.68%
Min EPS beat(4)-71.57%
Max EPS beat(4)18.3%
EPS beat(8)2
Avg EPS beat(8)-51.46%
EPS beat(12)6
Avg EPS beat(12)-27.41%
EPS beat(16)9
Avg EPS beat(16)-18.72%
Revenue beat(2)0
Avg Revenue beat(2)-7.43%
Min Revenue beat(2)-9.18%
Max Revenue beat(2)-5.67%
Revenue beat(4)0
Avg Revenue beat(4)-5.5%
Min Revenue beat(4)-9.18%
Max Revenue beat(4)-3.26%
Revenue beat(8)0
Avg Revenue beat(8)-7.44%
Revenue beat(12)1
Avg Revenue beat(12)-5.25%
Revenue beat(16)5
Avg Revenue beat(16)-1.26%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.36
P/FCF N/A
P/OCF N/A
P/B 8.25
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.54
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS2.9
BVpS0.12
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.58%
ROE -424.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 40.07%
FCFM N/A
ROA(3y)-25.41%
ROA(5y)-21.92%
ROE(3y)-189.74%
ROE(5y)-125.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.83%
GM growth 5Y-0.6%
F-Score2
Asset Turnover1.67
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.23%
Cap/Sales 0.03%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.42
Quick Ratio 0.77
Altman-Z -2.83
F-Score2
WACC8.98%
ROIC/WACCN/A
Cap/Depr(3y)23.78%
Cap/Depr(5y)23.52%
Cap/Sales(3y)0.25%
Cap/Sales(5y)0.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.22%
EPS Next Y49%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-6.19%
Revenue growth 3Y-3.35%
Revenue growth 5Y2.29%
Sales Q2Q%1.94%
Revenue Next Year5.44%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year69.51%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-6.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.01%
OCF growth 3YN/A
OCF growth 5YN/A